Analyzing the percentage of γδ T cells, and CD27- or CD27+ γδ T cells by FACS in PBMCs, we did not observe any differences between controls and MG patients for the percentage of γδ T cells (Figure 5A) or CD27- or CD27+ γδ T cells (Figures 5B, C). This evidence concerns the gene CD27 and myasthenia gravis.